申请人:Takeda Chemical Industries, Ltd.
公开号:EP1466902A1
公开(公告)日:2004-10-13
The present invention provides an androgen receptor antagonistic agent and a superior prophylactic or therapeutic agent for hormone-sensitive cancer, which contain a compound of the formula:
wherein, R1 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom; R2 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R3 is a hydrogen atom, a hydrocarbon group which may have substituent (s) , an acyl group or a heterocyclic group which may have substituent(s), R4 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, and R5 is a cyclic group which may have substituent(s); or a salt thereof, or its prodrug.
本发明提供了一种雄激素受体拮抗剂和一种激素敏感性癌症的高级预防或治疗剂,其中含有一种式化合物:
其中,R1 是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合的基团或通过硫原子结合的基团;R2 是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合 的基团或通过硫原子结合的基团; R3 是氢原子、烃基,该烃基可能具有取代基(s)、R4 是氢原子、通过碳原子结合的基团、通过氮原子结合的基团、通过氧原子结合的基团或通过硫原子结合的基团,R5 是可能带有取代基的环状基团;或其盐或其原药。